Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jan;12(1):1-10.
doi: 10.3109/17482968.2010.502940. Epub 2010 Aug 11.

The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

Ettore Beghi  1 , Adriano Chiò, Philippe Couratier, Jesùs Esteban, Orla Hardiman, Giancarlo Logroscino, Andrea Millul, Douglas Mitchell, Pierre-Marie Preux, Elisabetta Pupillo, Zorica Stevic, Robert Swingler, Bryan J Traynor, Leonard H Van den Berg, Jan H Veldink, Stefano Zoccolella; Eurals Consortium
Collaborators, Affiliations
Review

The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

Ettore Beghi et al. Amyotroph Lateral Scler. 2011 Jan.

Abstract

Abstract Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database of Systematic Reviews. 2007;(1):Art. No.: CD001447. doi: 10.1002/14651858.CD001447.pub2. - DOI - PubMed
    1. Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R. The epidemiology of ALS and the role of population based registries. BBA. 2006;1762:1150–7. - PubMed
    1. Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G, PARALS Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948–50. - PMC - PubMed
    1. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003;74:1258–61. - PMC - PubMed
    1. Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985–1988. Arch Neurol. 1991;48:589–93. - PubMed

Publication types

MeSH terms